Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia NCT04007029 CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 Years Jonsson Comprehensive Cancer Center View Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT01886859 Recurrent B-Cel...
Recurrent Chron...
Recurrent Small...
Refractory B-Ce...
Refractory Chro...
Refractory Smal...
Ibrutinib
Lenalidomide
18 Years - National Cancer Institute (NCI) View Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 Years Fred Hutchinson Cancer Center View Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center View Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00290004 Chronic Lymphoc...
Small Lymphocyt...
Leukemia
Lymphoma
motexafin gadol...
18 Years - Pharmacyclics LLC. View Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma NCT01381692 Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI) View Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT04659044 Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United View Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center View A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 Relapsed Non-Ho...
Refractory Non-...
Relapsed Chroni...
Refractory Chro...
Relapsed Follic...
Relapsed Margin...
Relapse Diffuse...
Relapsed Small ...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Richter Transfo...
Refractory Diff...
Transformed Non...
BGB-21447
18 Years - BeiGene View Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia NCT01008462 B-Cell Prolymph...
Hypodiploidy
Loss of Chromos...
Plasma Cell Leu...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Plasm...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Non-...
Refractory Plas...
Refractory Smal...
t(14;16)
t(4;14)
T-Cell Prolymph...
Waldenstrom Mac...
Allogeneic Bone...
Allogeneic Hema...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Peripheral Bloo...
Tacrolimus
Total-Body Irra...
- 75 Years Fred Hutchinson Cancer Center View NK Cells in Cord Blood Transplantation NCT01619761 Accelerated Pha...
Acute Biphenoty...
Acute Lymphobla...
Acute Myeloid L...
Chronic Phase C...
DS Stage II Pla...
DS Stage III Pl...
High Grade B-Ce...
ISS Stage II Pl...
ISS Stage III P...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Recurrent Chron...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Small...
Refractory Acut...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
Secondary Acute...
Therapy-Related...
Therapy-Related...
Allogeneic Hema...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Lenalidomide
Melphalan
Mycophenolate M...
Natural Killer ...
Rituximab
Tacrolimus
Total-Body Irra...
Umbilical Cord ...
- 75 Years M.D. Anderson Cancer Center View Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas NCT02332980 Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic View Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma NCT03010358 Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute View A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 Relapsed Non-Ho...
Refractory Non-...
Relapsed Chroni...
Refractory Chro...
Relapsed Follic...
Relapsed Margin...
Relapse Diffuse...
Relapsed Small ...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Richter Transfo...
Refractory Diff...
Transformed Non...
BGB-21447
18 Years - BeiGene View A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas NCT03277729 Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center View Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT02225275 Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Lenalidomide
Obinutuzumab
18 Years - M.D. Anderson Cancer Center View Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma NCT02568553 Recurrent Burki...
Recurrent Diffu...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Gray-...
Recurrent Mantl...
Recurrent Margi...
Recurrent Media...
Recurrent Non-H...
Recurrent Small...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Gray...
Refractory Mant...
Refractory Marg...
Refractory Medi...
Refractory Non-...
Refractory Smal...
Blinatumomab
Lenalidomide
18 Years - National Cancer Institute (NCI) View Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00100711 Chronic Lymphoc...
Small Lymphocyt...
Motexafin Gadol...
18 Years - Pharmacyclics LLC. View Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT04169737 Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Acalabrutinib
Obinutuzumab
Venetoclax
18 Years - M.D. Anderson Cancer Center View Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma NCT00005803 Prolymphocytic ...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Non-H...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
T-Cell Chronic ...
T-Cell Prolymph...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cyclosporine
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Therapeutic Aut...
Total-Body Irra...
- 75 Years Fred Hutchinson Cancer Center View Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL NCT03045328 Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Ibrutinib
Venetoclax
18 Years - Stanford University View Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT03961672 Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Duvelisib
18 Years - City of Hope Medical Center View Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma NCT01995669 Grade 3a Follic...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Laboratory Biom...
Lenalidomide
Obinutuzumab
18 Years - M.D. Anderson Cancer Center View Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT01886859 Recurrent B-Cel...
Recurrent Chron...
Recurrent Small...
Refractory B-Ce...
Refractory Chro...
Refractory Smal...
Ibrutinib
Lenalidomide
18 Years - National Cancer Institute (NCI) View CD19-Specific T Cells Post AlloSCT NCT03579888 B Acute Lymphob...
Recurrent B Acu...
Recurrent Chron...
Recurrent Diffu...
Recurrent Mantl...
Recurrent Non-H...
Recurrent Ph-Li...
Recurrent Prima...
Recurrent Small...
Refractory B Ac...
Refractory Chro...
Refractory Diff...
Refractory Mant...
Refractory Non-...
Refractory Ph-L...
Refractory Prim...
Refractory Smal...
Autologous CD19...
Cyclophosphamid...
Fludarabine
18 Years - 70 Years M.D. Anderson Cancer Center View A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas NCT03277729 Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center View Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery NCT02160015 Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Electrocardiogr...
Ibrutinib
Lenalidomide
Magnetic Resona...
Rituximab
18 Years - National Cancer Institute (NCI) View Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation NCT02420912 Loss of Chromos...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Nivolumab
18 Years - M.D. Anderson Cancer Center View Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia NCT04007029 CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 Years Jonsson Comprehensive Cancer Center View A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas NCT03277729 Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center View Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer NCT00789776 Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Diffuse Large B...
Previously Trea...
Recurrent Chron...
Recurrent Chron...
Recurrent Indol...
Recurrent Mantl...
Recurrent Plasm...
Recurrent Small...
Refractory Chro...
Refractory Hodg...
Refractory Plas...
Refractory Smal...
Waldenstrom Mac...
Allogeneic Bone...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Natural Killer ...
Tacrolimus
Total-Body Irra...
- Fred Hutchinson Cancer Center View Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma NCT00005803 Prolymphocytic ...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Non-H...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
T-Cell Chronic ...
T-Cell Prolymph...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cyclosporine
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Therapeutic Aut...
Total-Body Irra...
- 75 Years Fred Hutchinson Cancer Center View Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma NCT01381692 Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI) View Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT03961672 Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Duvelisib
18 Years - City of Hope Medical Center View Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas NCT02332980 Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic View Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma NCT03010358 Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute View Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00290004 Chronic Lymphoc...
Small Lymphocyt...
Leukemia
Lymphoma
motexafin gadol...
18 Years - Pharmacyclics LLC. View Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT04659044 Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United View Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia NCT02756897 Chronic Lymphoc...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Small Lymphocyt...
Ibrutinib
Laboratory Biom...
Venetoclax
18 Years - M.D. Anderson Cancer Center View CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma NCT04578600 Indolent B-Cell...
Recurrent B-Cel...
Recurrent Chron...
Recurrent Mucos...
Recurrent Folli...
Recurrent Hairy...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Chro...
Refractory Muco...
Refractory Foll...
Refractory Hair...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Recurrent Small...
Refractory Smal...
Lenalidomide
Obinutuzumab
Oral Azacitidin...
18 Years - University of California, Davis View Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL NCT03045328 Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Ibrutinib
Venetoclax
18 Years - Stanford University View Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia NCT04007029 CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 Years Jonsson Comprehensive Cancer Center View